BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raufi AG, Scott S, Darwish O, Harley K, Kahlon K, Desai S, Lu Y, Tran MH. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep 2016;8:6625. [PMID: 27781079 DOI: 10.4081/hr.2016.6625] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
2 de Holanda MI, Pôrto LC, Wagner T, Christiani LF, Palma LMP. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol 2017;36:2859-67. [PMID: 28905254 DOI: 10.1007/s10067-017-3823-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
3 Zickuhr L, Herlitz LC, Chatterjee S. A 22-Year-Old Woman With Systemic Lupus Erythematosus Presents With Two Damaged Kidneys, One Seizure, No Platelets, and Many Possible Diagnoses. Arthritis Care Res (Hoboken) 2018;70:1686-93. [PMID: 29579358 DOI: 10.1002/acr.23561] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Chao SH, Chang YL, Yen JC, Liao HT, Wu TH, Yu CL, Tsai CY, Chou YC. Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis. Exp Hematol Oncol 2020;9:6. [PMID: 32322437 DOI: 10.1186/s40164-020-00163-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
6 Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 2020;21:245. [PMID: 32605540 DOI: 10.1186/s12882-020-01888-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Yue C, Su J, Gao R, Wen Y, Li C, Chen G, Zhang X, Li X. Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus–associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles. J Rheumatol 2018;45:1549-56. [DOI: 10.3899/jrheum.170811] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
9 Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol 2017;13:538-47. [DOI: 10.1038/nrrheum.2017.125] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 19.0] [Reference Citation Analysis]
10 Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum 2019;49:74-83. [PMID: 30598332 DOI: 10.1016/j.semarthrit.2018.11.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 11.8] [Reference Citation Analysis]
11 Nasonov EL, Reshetnyak TM, Alekberova ZS. [Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity]. Ter Arkh 2020;92:4-14. [PMID: 32598770 DOI: 10.26442/00403660.2020.05.000697] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]